Anti-IL-6 and anti-IL-6R, monoclonal antibodies currently approved for treatment of rheumatoid arthritis by inhibiting JAK pathway signaling. In vitro anti-IL-6 antibody treatment of LGLL patients’ PBMCs led to malignant cell apoptosis (12). The gene discussed is IL6R; the disease is T-cell large granular lymphocyte leukemia.